



Xiaflex

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: _____ Date: _____
Patient's ID: _____ Patient's Date of Birth: _____
Physician's Name: _____
Specialty: _____ NPI#: _____
Physician Office Telephone: _____ Physician Office Fax: _____

Referring Provider Info: Same as Requesting Provider

Name: _____ NPI#: _____
Fax: _____ Phone: _____

Rendering Provider Info: Same as Referring Provider Same as Requesting Provider

Name: _____ NPI#: _____
Fax: _____ Phone: _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____ kg
Patient Height: _____ cm

Please indicate the place of service for the requested drug:

- Ambulatory Surgical (POS Code 24)
- Off Campus Outpatient Hospital (POS Code 19)
- Office (POS Code 11)
- Home (POS Code 12)
- On Campus Outpatient Hospital (POS Code 22)

Drug Information:

Strength/Measure _____ Units ml Gm mg ea Un
Directions(sig) _____ Route of administration _____
Dosing frequency _____

What is the ICD-10 code? _____

Clinical Criteria Questions:

1. What is the diagnosis?
 Dupuytren's contracture, Continue to 2
 Peyronie's disease, Continue to 10
 Other, please specify. _____, No further questions

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Xiaflex SGM 3043-A – 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org



2. Prior to initiating the current course of treatment for the cord with the requested medication, did/does the patient have a finger flexion contracture with a palpable cord in a metacarpophalangeal joint or a proximal interphalangeal joint? **ACTION REQUIRED:** If Yes, attach supporting chart note(s) or medical record indicating the affected joint.

- Yes - In a metacarpophalangeal joint **ACTION REQUIRED:** Submit supporting documentation, Continue to 3
- Yes - In a proximal interphalangeal joint **ACTION REQUIRED:** Submit supporting documentation, Continue to 3
- No, Continue to 3

3. Prior to initiating the current course of treatment for the cord with the requested medication, was/is the contracture at least 20 degrees? **ACTION REQUIRED:** If Yes, attach supporting chart note(s) or medical record indicating the degree of pretreatment contracture. **ACTION REQUIRED:** Submit supporting documentation

- Yes, Continue to 4
- No, Continue to 4

4. Prior to initiating the current course of treatment for the cord with the requested medication, did the patient have a positive table top test, defined as the inability to simultaneously place the affected finger(s) and palm flat against a table? **ACTION REQUIRED:** If Yes, attach supporting chart note(s) or medical record indicating a positive table top test.

- Yes, Continue to 5
- No, Continue to 5

5. Is the patient continuing with a treatment course for the same cord?

- Yes - continuing with a treatment course for the same cord, Continue to 6
- No - starting a treatment course for new cord, Continue to 7
- No - starting a treatment course for recurrence in a previously treated cord, Continue to 7
- Other, please specify. _____, No further questions

6. How many injections has the patient received as part of the current treatment course? **ACTION REQUIRED:** If less than 3 injections, attach supporting chart note(s) or medical record indicating the number of injections the patient has received for each cord being treated.

_____ injections per current treatment course, Continue to 7

7. Will the requested drug be used for cosmetic use (e.g., cellulite reduction treatment)?

- Yes, Continue to 8
- No, Continue to 8

8. Will the requested medication be administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture?

- Yes, Continue to 9
- No, Continue to 9

9. Will the patient receive up to 3 injections maximum (4 weeks apart) as part of the current treatment?

- Yes, No Further Questions
- No, No Further Questions

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Xiaflex SGM 3043-A – 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org



10. Does the patient have stable Peyronie's disease without clinical changes (e.g., worsening curvature) for at least three months?

- Yes, *Continue to 11*
- No, *Continue to 11*

11. Prior to initiating therapy with the requested medication, did/does the patient have a palpable plaque and curvature deformity of at least 30 degrees and less than 90 degrees? **ACTION REQUIRED:** If Yes, attach supporting chart note(s) or medical record indicating the pretreatment deformity curvature and the presence of a palpable plaque.

- Yes, *Continue to 12*
- No, *Continue to 12*

12. Does the patient have intact erectile function (with or without medication)? **ACTION REQUIRED:** If Yes, attach supporting chart note(s) or medical record indicating intact erectile function (with or without medication).

- Yes, *Continue to 13*
- No, *Continue to 13*

13. Is the patient 18 years of age or older?

- Yes, *Continue to 14*
- No, *Continue to 14*

14. Is the patient continuing treatment with the requested medication for Peyronie's disease?

- Yes, *Continue to 15*
- No, *Continue to 17*

15. What is the current curvature of deformity? **ACTION REQUIRED:** If 15 degrees or greater, attach supporting chart note(s) or medical record indicating the current deformity curvature.

_____ degrees, *No further questions*

16. How many injections has the patient received, including any injections patient already received during current and any previous treatment? **ACTION REQUIRED:** If less than 8 injections, attach supporting chart note(s) or medical record indicating the number of injections the patient has received.

_____ injections, *Continue to 17*

17. Will the requested medication be used for cosmetic use (e.g., cellulite reduction treatment)?

- Yes, *Continue to 18*
- No, *Continue to 18*

18. Will the requested medication be administered by a healthcare provider experienced in the treatment of urological disease?

- Yes, *Continue to 19*
- No, *Continue to 19*

19. Will the requested medication be administered by a healthcare provider who has completed the requested medication REMS program requirements?

- Yes, *Continue to 20*
- No, *Continue to 20*

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Xiaflex SGM 3043-A – 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org



20. Will the patient receive a maximum of one treatment course with a total of 8 injections or less, including any injections patient already received during current and any previous treatment?

Yes, *No Further Questions*

No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Xiaflex SGM 3043-A – 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org